TGM4 and nasopharyngeal carcinoma: Based on these data, CGP and TGP were approved as first-line treatment options for cases experiencing R/M NPC by the National Medical Products Administration of China and the Chinese Society of Clinical Oncology and included in the protocols for NPC interventions, version20211,.2